PTK2 and cancer: Given the limitation of clinical efficacy of this FAK inhibitor against epithelia-origin human cancers (Jones et al., 2015; Xu et al., 2017; Gerber et al., 2020), we examined the combinatorial inhibition strategy for this inhibitor-based targeting by performing cell viability-based chemical inhibitor screening.